SCHEMBL17301565

SCHEMBL17301565

CC(C)CCNC(=O)CCCO

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
PKM P14618 1/20 0.57
CNR1 P21554 4/20 0.54
HPGD P15428 1/20 0.54
ALDH1A1 P00352 1/20 0.48
NAMPT P43490 2/20 0.46
CNR2 P34972 1/20 0.46
NAAA Q02083 1/20 0.44
HTT P42858 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
NMT2 O60551 1/20 0.43
NMT1 P30419 1/20 0.43
TSHR P16473 1/20 0.41
PTPN1 P18031 1/20 0.41
ANPEP P15144 2/20 0.41
RNPEP Q9H4A4 2/20 0.41
DNPEP Q9ULA0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10443552 0.94 LMNA (0.55) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL13328249 0.88 LMNA (0.60) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL26733411 0.88 ALDH1A1 (0.52) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL28340107 0.86 LMNA (0.58) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL7257878 0.85 ALDH1A1 (0.58) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL8847697 0.84 CNR1 (0.67) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL24826063 0.84 CNR1 (0.52) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL16390142 0.83 CNR1 (0.49) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL11452609 0.83 ALDH1A1 (0.61) LMNAPKMCNR1HPGDALDH1A1
SCHEMBL24341572 0.82 LMNA (0.55) LMNAPKMCNR1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200207753-A1 Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof SPG THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207753-A1 Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof AR, ESRRA, ESRRB LMNA 3880/4885PKM 1854/4885CNR1 73/4885
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP SQLE, CTRL, ENO1 LMNA 1188/4885PKM 1929/4885CNR1 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.